Personalis (NASDAQ:PSNL) Announces Earnings Results
by Doug Wharley · The Cerbat GemPersonalis (NASDAQ:PSNL – Get Free Report) released its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06), FiscalAI reports. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million.
Here are the key takeaways from Personalis’ conference call:
- Personalis reported strong clinical volume momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), surpassed >1,000 ordering physicians in the quarter, and reconfirmed a 2026 clinical volume target of 43,000–45,000 tests.
- Q1 revenue was $15.5M (down ~25% YoY) and gross margin compressed to 1.8% due to unreimbursed scaling; net loss widened to $30M and full-year net loss is guided to about $105M with ~$100M expected cash usage despite a $233M cash balance.
- Reimbursement and clinical evidence progress: Medicare coverage for breast and lung surveillance is live, MolDX submissions are pending for neoadjuvant breast and pan‑cancer IO, and presented data (NEOPRISM‑CRC, DARWIN‑2, 10k real‑world cohort) highlighted high negative predictive value and the value of ultrasensitivity.
- Biopharma MRD momentum and backlog are growing: Q1 biopharma MRD revenue was $3.1M with management targeting $20M–$21M for the full year, expecting most MRD revenue to ramp in H2 as several large trials commence.
Personalis Trading Down 1.3%
Shares of PSNL stock traded down $0.08 during mid-day trading on Thursday, reaching $5.99. The stock had a trading volume of 1,509,398 shares, compared to its average volume of 2,054,222. Personalis has a 12-month low of $3.84 and a 12-month high of $11.50. The company has a market cap of $627.03 million, a P/E ratio of -6.58 and a beta of 1.96. The business has a 50-day simple moving average of $6.93 and a 200 day simple moving average of $8.23.
Analyst Ratings Changes
PSNL has been the subject of a number of research analyst reports. Morgan Stanley dropped their price target on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Needham & Company LLC raised their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Guggenheim raised their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research raised their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.
Get Our Latest Stock Analysis on PSNL
Institutional Trading of Personalis
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. increased its position in Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Kennedy Capital Management LLC increased its position in Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares in the last quarter. Millennium Management LLC increased its position in Personalis by 11.0% during the 3rd quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock worth $7,894,000 after purchasing an additional 120,027 shares in the last quarter. Finally, State Street Corp increased its position in Personalis by 13.4% during the 4th quarter. State Street Corp now owns 1,050,590 shares of the company’s stock worth $8,363,000 after purchasing an additional 124,243 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.
Personalis Company Profile
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.